Sawsan Rashdan, Associate Professor at UT Southwestern Medical Center, shared on LinkedIn:
“Thrilled to share that our investigator-initiated Phase II multi-center trial, where I served as the Primary Investigator, studying osimertinib + consolidative radiotherapy in advanced EGFR-mutated NSCLC has just been published in eClinicalMedicine, The Lancet’s journal!
This collaborative effort between UT Southwestern Medical Center and City of Hope provides important new insights into optimizing first-line treatment strategies for patients with EGFR-mutated non-small cell lung cancer.
I am deeply grateful to my mentor, Dr. David Gerber, whose guidance and support were invaluable throughout this journey. Grateful as well to my colleagues, collaborators, and patients who made this milestone possible.”
More posts featuring Sawsan Rashdan.